PBYI Puma Biotechnology Inc - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 6, 2026
$9,51
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$4,5852 haftanın en düşüğü
$10,1052 haftanın en yükseği
Piyasa Değeri (MRQ)
$486M
P/E (TTM)
18.3
Hisse Başına Kâr (TTM)
$0.52
Gelir (TTM)
$231M
rozetleriniz
52 Haftlık Aralık
$5–$10
Analist Derecelendirmesi
HOLD
Fiyat Hedefi
$6
P/E
18.3
ROE
22.0%
Net Kâr Marjı
11.6%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
PBYI Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$9.51
Piyasa Değeri (MRQ)
$486M
P/E (TTM)
18.3
Hisse Başına Kâr (TTM)
$0.52
Gelir (TTM)
$231M
ROE (TTM)
22.0%
D/E Borç/Özsermaye (MRQ)
0.0
52 Haftlık Aralık
$5–$10
PBYI Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Puma Biotechnology Inc - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Creation
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. Cougar further developed abiraterone before the company was sold to Johnson & Johnson in 2009. Auerbach brought many Cougar employees with him after founding Puma in 2010.
Funding for development
In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.
As part of an approximately $60 million financing round in October 2011, Puma entered into a reverse merger with the shell company Innovative Acquisitions Corp., formed in 2007. In April 2012 the company's stock began trading over the counter. In October 2012 the company raised around $138 million and its shares were listed on the New York Stock Exchange.
In 2016 Puma discovered that Robert Gadimian, senior director of regulatory affairs, had twice bought and sold stock based on his knowledge of unpublished clinical trial results; Puma quickly fired him after conducting an internal investigation and reported the insider trading to the SEC.
Approval and licensing of neratinib
In March 2016 Puma held a pre-NDA meeting with the FDA in which the FDA raised concerns about the design and conduct of clinical trials that Puma had run and recommended that Puma not file the NDA with that data.
Puma did file the NDA, and in May 2017 an FDA review panel recommended that the FDA approve neratinib but raised concerns that the intended use was too broad and should be limited to people with specific mutations. The FDA's briefing document to the panel had raised concerns about the marginal benefit of the drug and the side effects. In July 2017 the FDA approved neratinib for use in preventing the return of breast cancer after treatment that included trastuzumab and without any need for genetic testing, and with warnings about the risk of severe diarrhea. U.S. sales of neratinib totaled $200.5 million in 2018.
In January 2018 an EMA committee gave a negative review to neratinib. In June 2018 this same EMA committee recommended the approval of neratinib, which received European Commission (EC) approval in September 2018.
In 2019 Puma licensed commercialization rights in Europe and part of Africa to Pierre Fabre for an upfront payment of $60 million and milestone payments that could reach $345 million. Previously, Puma licensed rights in Greater China to CANbrdige Life Sciences, rights in Israel to Medison Pharma, rights in Canada to Knight Therapeutics, rights in South East Asian to Specialised Therapeutics and rights in Latin America to Pint Pharma.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar179
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$228M2017-12-31 → 2025-12-31
Hisse Başına Kâr$0.612020-12-31 → 2025-12-31
Serbest Nakit Akışı$42M2016-12-31 → 2025-12-31
Net kar marjı11.6%2017-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | PBYI | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 18.35Y ort. ≈5.0 | ≈5.0 | · | · | |
| F/S (TTM) | 2.15Y ort. ≈0.8 | ≈0.8 | 7.3 | Düşük değerli | |
| F/D (MRQ) | 3.55Y ort. ≈-6.8 | ≈-6.8 | 3.0 | Adil değer | |
| EV / EBITDA | 11.05Y ort. ≈26.1 | ≈26.1 | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | 11.85Y ort. ≈2.7 | ≈2.7 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 11.85Y ort. ≈2.7 | ≈2.7 | · | · | |
| EV / Gelir (TTM) | 1.75Y ort. ≈0.8 | ≈0.8 | · | · | |
| EV / FCF (TTM) | 9.55Y ort. ≈2.1 | ≈2.1 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 5.4 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | PBYI | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 13.2%5Y ort. ≈10.9% | ≈10.9% | -191.1% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | 16.3%5Y ort. ≈10.9% | ≈10.9% | -184.7% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | 13.5%5Y ort. ≈4.9% | ≈4.9% | -113.8% | En üst düzey | |
| Net Kâr Marjı (TTM) | 11.6%5Y ort. ≈4.9% | ≈4.9% | -181.7% | En üst düzey | |
| ROA (TTM) | 13.8%5Y ort. ≈5.1% | ≈5.1% | -17.8% | En üst düzey | |
| ROE (TTM) | 22.0%5Y ort. ≈109.2% | ≈109.2% | -18.7% | En üst düzey | |
| ROIC | 21.2%5Y ort. ≈13.5% | ≈13.5% | -22.3% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | PBYI | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.05Y ort. ≈-6.5 | ≈-6.5 | · | · | |
| Cari Oran (MRQ) | 2.95Y ort. ≈1.6 | ≈1.6 | 12.6 | Düşük likidite | |
| Cari Oran (MRQ) | 2.65Y ort. ≈1.5 | ≈1.5 | 2.9 | Düşük likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.05Y ort. ≈-6.7 | ≈-6.7 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | PBYI | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -0.91%5Y ort. ≈0.56% | ≈0.56% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 0.05%5Y ort. ≈-0.50% | ≈-0.50% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 0.29% | · | · | · | |
| EPS YoY (EPS YB) | -1.6% | · | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 2.8%5Y ort. ≈359831.0% | ≈359831.0% | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | 2396.3% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | PBYI | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 1.15Y ort. ≈1.0 | ≈1.0 | 0.1 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 8.25Y ort. ≈9.7 | ≈9.7 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 5.35Y ort. ≈6.3 | ≈6.3 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.3M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
171.8%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 5, 2026 | $0.16 | $0.04 | 292.2% |
| 31 Mart 2026 | $-0.07 | $-0.13 | 47.2% | |
| 31 Aralık 2025 | $0.26 | $0.23 | 12.3% | |
| 30 Eylül 2025 | $0.17 | $0.05 | 270.4% | |
| 30 Haziran 2025 | $0.12 | $0.10 | 14.6% | |
| 31 Mart 2025 | $0.06 | $-0.02 | 394.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Cost of Revenue | $58M | $64M | $63M | $55M | $64M | $39M | $37M | $35M | $6M | |
| R&D Expense | · | · | · | · | $72M | $98M | $133M | $165M | $208M | |
| SG&A Expense | $71M | $80M | $90M | $90M | $116M | $118M | $142M | $146M | $107M | |
| Operating Expenses | $191M | $200M | $203M | $204M | $252M | $256M | $311M | $346M | $320M | |
| Operating Income | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M | |
| Interest Expense | · | · | $13M | $12M | $13M | $14M | $15M | $11M | $720.0K | |
| Interest Income | $4M | $5M | $3M | $813.0K | $160.0K | $489.0K | $3M | $2M | $1M | |
| Other Non-op | $1M | $862.0K | $759.0K | $-28.0K | $292.0K | $367.0K | $128.0K | $-714.0K | $-101.0K | |
| Pretax Income | $36M | $24M | $23M | $457.0K | $-29M | $-60M | $-76M | $-114M | · | |
| Income Tax | $5M | $-6M | $1M | $455.0K | $324.0K | $207.0K | $53.0K | $17.0K | $0 | |
| Net Income | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75595.00 | · | · | |
| EPS (Diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · | |
| Shares (Basic) | 50,011,485 | 48,648,701 | 47,134,331 | 44,674,501 | 40,638,852 | 39,576,107 | · | · | · | |
| Shares (Diluted) | 50,653,283 | 49,100,433 | 47,550,852 | 44,929,998 | 40,638,852 | 39,576,107 | · | · | · | |
| EBITDA | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30M | $69M | $85M | $76M | $63M | $85M | $60M | $108M | $82M | |
| Short-term Investments | $68M | $32M | $11M | $5M | $19M | $8M | $52M | $57M | · | |
| Receivables | $54M | $32M | $48M | $40M | $33M | $26M | $29M | $21M | $10M | |
| Inventory | $6M | $9M | $7M | $5M | $7M | $3M | $3M | $3M | $2M | |
| Prepaid Expense | $4M | $6M | $4M | $6M | $9M | $11M | $13M | $12M | $13M | |
| Other Current Assets | $256.0K | $91.0K | $912.0K | $2M | $447.0K | $4M | $323.0K | $2M | · | |
| Current Assets | $163M | $148M | $156M | $134M | $140M | $146M | $166M | $203M | $106M | |
| PP&E (Net) | $187.0K | $515.0K | $855.0K | $1M | $2M | $2M | $3M | $4M | $4M | |
| PP&E (Gross) | $5M | $8M | $9M | $9M | $9M | $9M | $9M | $9M | $9M | |
| Accum. Depreciation | $5M | $8M | $8M | $7M | $7M | $6M | $6M | $5M | $4M | |
| Intangibles | $41M | $51M | $61M | $71M | $66M | $74M | $40M | $44M | $48M | |
| Total Assets | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Accounts Payable | $5M | $6M | $7M | $6M | $11M | $12M | $19M | $21M | $28M | |
| Accrued Liabilities | $50M | $37M | $53M | $53M | $93M | $61M | $69M | $46M | $31M | |
| Current Liabilities | $81M | $96M | $99M | $77M | $110M | $114M | $91M | $67M | $58M | |
| Capital Leases | $5M | $1M | $7M | $12M | $16M | $20M | $23M | · | · | |
| Other Non-current Liabilities | $0 | $121.0K | $121.0K | · | · | · | · | · | · | |
| Total Liabilities | $86M | $121M | $177M | $200M | $229M | $250M | $217M | $225M | $112M | |
| Long-term Debt | $23M | $68M | $102M | $102M | $102M | $84M | $95M | $152M | $48M | |
| Total Debt | $23M | $67M | $100M | $98M | $97M | $98M | · | · | · | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.28B | $-1.31B | $-1.35B | $-1.37B | $-1.37B | $-1.34B | $-1.28B | $-1.20B | $-1.09B | |
| AOCI | $36.0K | $6.0K | $-4.0K | $0 | $-2.0K | $0 | $62.0K | $-12.0K | · | |
| Stockholders' Equity | $130M | $92M | $53M | $22M | $-2M | $-6M | $17M | $34M | $53M | |
| Liabilities + Equity | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Shares Outstanding | 50,408,023 | 49,105,834 | 47,646,787 | 46,345,660 | 41,175,507 | 40,086,387 | 39,203,304 | 38,325,037 | 37,594,851 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11M | $12M | $12M | $10M | $11M | $10M | $8M | $7M | $3M | |
| Stock-based Comp | $7M | $8M | $10M | $12M | $33M | $37M | $57M | $87M | $109M | |
| Deferred Tax | $3M | $-7M | $0 | $0 | · | · | · | · | · | |
| Amort. of Intangibles | $10M | $10M | $8M | $8M | $8M | $6M | $4M | $4M | $2M | |
| Operating Cash Flow | $42M | $39M | $27M | $-16M | $21M | $773.0K | $22M | $-24M | $-172M | |
| CapEx | $71.0K | $56.0K | $140.0K | $0 | $0 | $46.0K | $306.0K | $439.0K | $431.0K | |
| Investing Cash Flow | $-36M | $-20M | $-19M | $7M | $-11M | $33M | $5M | $-58M | $-15M | |
| Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Financing Cash Flow | $-45M | $-34M | $0 | $12M | $-32M | $-10M | $-67M | $108M | $75M | |
| Net Change in Cash | $-40M | $-15M | $8M | $4M | $-22M | $24M | $-40M | $27M | $-113M | |
| Taxes Paid | $1M | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $42M | $39M | $27M | $-16M | $21M | · | · | $-25M | $-173M | |
| Levered FCF | · | · | $14M | $-16M | $8M | · | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| Net Margin | 13.6% | 13.1% | 9.2% | 0.00% | -11.5% | -26.7% | -27.8% | -45.2% | -1054.6% | |
| Pretax Margin | 15.7% | 10.5% | 9.6% | 0.20% | -11.4% | -26.6% | · | · | · | |
| EBITDA Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| ROA | 14.5% | 13.6% | 9.5% | 0.00% | -12.4% | -25.0% | -30.6% | -53.5% | -139.6% | |
| ROE | 26.5% | 37.1% | 46.8% | 0.01% | 435.8% | 1873.7% | -436.4% | -283.2% | -221.9% | |
| ROIC | 21.2% | 24.4% | 20.3% | 0.09% | 1.4% | -33.0% | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 | 1.3 | 1.8 | 3.0 | 1.8 | |
| Quick Ratio | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 | 1.0 | 1.5 | 2.8 | 1.6 | |
| Debt / Equity | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 | -16.5 | · | · | · | |
| LT Debt / Equity | 0.0 | 0.2 | 1.2 | 4.5 | -39.7 | -14.1 | · | · | · | |
| Interest Coverage | · | · | 2.4 | 2.0 | 0.1 | -2.2 | -2.6 | -8.6 | -406.1 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 1.0 | 1.0 | 1.0 | 1.1 | 0.9 | 1.1 | 1.2 | 0.1 | |
| Inventory Turnover | 8.2 | 8.2 | 10.8 | 9.5 | 12.1 | · | · | 14.9 | 5.5 | |
| Receivables Turnover | 5.3 | 5.8 | 5.3 | 6.3 | 8.7 | 8.3 | 11.0 | 16.5 | 5.7 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.59 | $1.88 | $1.12 | $0.52 | $-0.06 | $-0.15 | $0.45 | $0.90 | $1.42 | |
| Revenue / Share | $4.51 | $4.69 | $4.96 | $5.08 | · | · | · | · | · | |
| Cash Flow / Share | $0.83 | $0.79 | $0.57 | $-0.35 | · | · | · | · | · | |
| Cash / Share | $0.59 | $1.41 | $1.78 | $1.85 | $1.57 | $2.13 | $1.53 | $2.83 | $2.17 | |
| EPS (TTM) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.91% | -2.2% | 3.3% | -9.9% | 12.5% | · | · | · | · | |
| Revenue CAGR 3Y | 0.05% | -3.1% | 1.5% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.29% | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.6% | 37.8% | · | · | · | · | · | · | · | |
| Net Income YoY | 2.8% | 40.2% | 1079450.0% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 2396.3% | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Net Income TTM | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| Market Cap | $300M | $150M | $206M | $174M | $122M | $411M | $343M | $780M | $3.72B | |
| Enterprise Value | $225M | $116M | $210M | $191M | $137M | $416M | · | · | · | |
| P/E | 9.8 | 4.9 | 9.6 | · | -4.2 | -6.8 | · | · | · | |
| P/S | 1.3 | 0.6 | 0.9 | 0.8 | 0.5 | 1.8 | 1.3 | 3.1 | 134.2 | |
| P/B | 2.3 | 1.6 | 3.9 | 8.1 | -49.8 | -69.1 | 19.6 | 22.7 | 69.7 | |
| P / Tangible Book | 3.4 | 3.7 | · | · | · | · | · | · | · | |
| P / Cash Flow | 7.2 | 3.8 | 7.6 | -11.0 | 5.9 | 532.1 | 15.3 | -32.4 | -21.5 | |
| P / FCF | 7.2 | 3.9 | 7.7 | -11.0 | 5.9 | · | · | -31.8 | -21.5 | |
| EV / EBITDA | 6.0 | 3.7 | 6.4 | 8.1 | 106.1 | -13.7 | · | · | · | |
| EV / FCF | 5.4 | 3.0 | 7.8 | -12.1 | 6.6 | · | · | · | · | |
| EV / Revenue | 1.0 | 0.5 | 0.9 | 0.8 | 0.5 | 1.8 | · | · | · | |
| Earnings Yield | 10.2% | 20.3% | 10.4% | 0.00% | -23.7% | -14.8% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $45M | $75M | $54M | $52M | $46M | $59M | $81M | $47M | $44M | $72M | $56M | $55M | $53M | $66M | $57M | |
| Cost of Revenue | $12M | $10M | $23M | $12M | $12M | $11M | $14M | $29M | $11M | $11M | $24M | $13M | $12M | $13M | $17M | $12M | |
| SG&A Expense | $18M | $18M | $18M | $17M | $18M | $18M | $17M | $17M | $25M | $22M | $20M | $23M | $24M | $22M | $25M | $24M | |
| Operating Expenses | $49M | $49M | $58M | $45M | $46M | $42M | $46M | $58M | $49M | $46M | $57M | $48M | $50M | $48M | $56M | $55M | |
| Operating Income | $8M | $-4M | $17M | $10M | $7M | $4M | $13M | $22M | $-2M | $-2M | $15M | $9M | $5M | $4M | $10M | $2M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $3M | · | $3M | $3M | $3M | · | $3M | |
| Interest Income | $831.0K | $1M | $977.0K | $1M | $956.0K | $1M | $1M | $1M | $1M | $972.0K | $719.0K | $689.0K | $660.0K | $537.0K | $519.0K | $216.0K | |
| Other Non-op | $9.0K | $130.0K | $143.0K | $115.0K | $410.0K | $359.0K | $268.0K | $347.0K | $156.0K | $91.0K | $641.0K | $74.0K | $86.0K | $-42.0K | $-204.0K | $64.0K | |
| Pretax Income | $8M | $-3M | $17M | $9M | $6M | $3M | $12M | $21M | $-4M | $-5M | $13M | $6M | $2M | $2M | $-5M | $-293.0K | |
| Income Tax | · | · | · | · | · | · | $-7M | $291.0K | $378.0K | $220.0K | $536.0K | $213.0K | $187.0K | $147.0K | $294.0K | $67.0K | |
| Net Income | $8M | $-4M | $13M | $9M | $6M | $3M | $19M | $20M | $-5M | $-5M | $12M | $6M | $2M | $1M | $-6M | $-360.0K | |
| EPS (Basic) | $0.16 | $-0.07 | $0.26 | $0.18 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.26 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| EPS (Diluted) | $0.16 | $-0.07 | $0.26 | $0.17 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.25 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| Shares (Basic) | 50,939,946 | 50,845,130 | · | 50,339,456 | 49,700,217 | 49,595,697 | · | 49,008,464 | 48,292,414 | 48,189,256 | · | 47,520,338 | 46,759,062 | 46,636,083 | · | 45,567,739 | |
| Shares (Diluted) | 52,596,589 | 50,845,130 | · | 50,929,893 | 50,144,704 | 49,906,341 | · | 49,173,361 | 48,292,414 | 48,189,256 | · | 47,819,234 | 47,201,185 | 47,157,904 | · | 45,567,739 | |
| EBITDA | $8M | $-4M | · | $10M | $7M | · | · | $22M | $-2M | $-2M | · | $9M | $5M | $4M | · | $2M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37M | $36M | $30M | $54M | $55M | $63M | $69M | $67M | $67M | $77M | · | $82M | $60M | $61M | · | $78M | |
| Short-term Investments | $57M | $65M | $68M | $41M | $41M | $30M | $32M | $29M | $30M | $30M | · | $3M | $14M | $10M | · | $0 | |
| Receivables | $34M | $26M | $54M | $34M | $26M | $25M | $32M | $55M | $28M | $25M | · | $29M | $31M | $31M | · | $28M | |
| Inventory | $13M | $9M | $6M | $9M | $9M | $9M | $9M | $3M | $9M | $7M | · | $6M | $8M | $4M | · | $5M | |
| Prepaid Expense | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $3M | $3M | $4M | · | $4M | $5M | $5M | · | $7M | |
| Other Current Assets | $199.0K | $196.0K | $256.0K | $230.0K | $73.0K | $98.0K | $91.0K | $236.0K | $241.0K | $255.0K | · | $2M | $573.0K | $449.0K | · | $4M | |
| Current Assets | $145M | $142M | $163M | $144M | $137M | $133M | $148M | $157M | $138M | $143M | · | $125M | $119M | $112M | · | $122M | |
| PP&E (Net) | $103.0K | $124.0K | $187.0K | $305.0K | $388.0K | $474.0K | $515.0K | $601.0K | $680.0K | $757.0K | · | $907.0K | $977.0K | $1M | · | $1M | |
| PP&E (Gross) | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $9M | $9M | $9M | · | $9M | $9M | $9M | · | $9M | |
| Accum. Depreciation | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | $7M | |
| Intangibles | · | · | $41M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Accounts Payable | $3M | $8M | $5M | $6M | $5M | $6M | $6M | $8M | $14M | $9M | · | $5M | $8M | $9M | · | $15M | |
| Accrued Liabilities | $45M | $38M | $50M | $37M | $32M | $27M | $37M | $51M | $39M | $38M | · | $34M | $35M | $34M | · | $40M | |
| Current Liabilities | $50M | $60M | $81M | $83M | $79M | $87M | $96M | $110M | $104M | $98M | · | $67M | $60M | $48M | · | $60M | |
| Capital Leases | $4M | $5M | $5M | $5M | $0 | $0 | $1M | $3M | $4M | $6M | · | $8M | $10M | $11M | · | $13M | |
| Other Non-current Liabilities | · | · | $0 | $0 | $0 | $0 | $121.0K | $121.0K | $121.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $54M | $64M | $86M | $88M | $90M | $99M | $121M | $150M | $156M | $163M | · | $165M | $170M | $170M | · | $177M | |
| Long-term Debt | $0 | $11M | $23M | $34M | $45M | $57M | $67M | $79M | $91M | $102M | · | $102M | $102M | $102M | · | $102M | |
| Total Debt | $0 | $11M | · | $34M | $45M | · | · | $78M | $89M | $100M | · | $99M | $99M | $99M | · | $98M | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | · | $5.0K | $5.0K | $5.0K | · | $5.0K | |
| Retained Earnings | $-1.28B | $-1.29B | $-1.28B | $-1.30B | $-1.31B | $-1.31B | $-1.31B | $-1.33B | $-1.35B | $-1.35B | · | $-1.36B | $-1.36B | $-1.37B | · | $-1.36B | |
| AOCI | $-45.0K | $-31.0K | $36.0K | $19.0K | $-14.0K | $-11.0K | $6.0K | $26.0K | $-32.0K | $-26.0K | · | $-4.0K | $-6.0K | · | · | $0 | |
| Stockholders' Equity | $139M | $128M | $130M | $115M | $105M | $97M | $92M | $71M | $49M | $51M | $53M | $39M | $30M | $26M | $22M | $22M | |
| Liabilities + Equity | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Shares Outstanding | 51,102,687 | 50,879,204 | 50,408,023 | 50,384,274 | 49,892,725 | 49,615,174 | 49,105,834 | 49,067,348 | 48,460,120 | 48,214,663 | 47,646,787 | 47,542,790 | 46,947,153 | 46,663,599 | 46,345,660 | 45,608,814 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $2M | $3M | $3M | $3M | |
| Amort. of Intangibles | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $800.0K | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $2M | $15M | $14M | $10M | $14M | $4M | $16M | $11M | $1M | $11M | $10M | $11M | $3M | $3M | $8M | $17M | |
| CapEx | $0 | $0 | $-36.0K | $26.0K | $20.0K | $61.0K | $16.0K | $20.0K | $20.0K | $0 | $45.0K | $27.0K | · | · | $0 | $0 | |
| Investing Cash Flow | $8M | $2M | $-27M | $506.0K | $-11M | $2M | $-2M | $259.0K | $703.0K | $-19M | $-8M | $11M | $-5M | $-17M | $-12M | $8M | |
| Financing Cash Flow | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $0 | $0 | $0 | $0 | $0 | $2M | $-53.0K | |
| Net Change in Cash | $-2M | $7M | $-24M | $-1M | $-8M | $-6M | $2M | $114.0K | $-10M | $-8M | $2M | $22M | $-1M | $-15M | $-2M | $25M | |
| Free Cash Flow | · | $15M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| Net Margin | 14.5% | -8.4% | · | 16.2% | 11.2% | · | · | 25.2% | -9.6% | -11.0% | · | 10.3% | 3.9% | 2.6% | · | -0.63% | |
| Pretax Margin | 14.6% | -7.6% | · | 17.0% | 11.8% | · | · | 25.6% | -8.8% | -10.5% | · | 10.7% | 4.2% | 2.9% | · | -0.51% | |
| EBITDA Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| ROA | 4.2% | -1.9% | · | 4.2% | 2.9% | · | · | 9.6% | -2.2% | -2.4% | · | 2.9% | 1.1% | 0.71% | · | -0.17% | |
| ROE | 6.7% | -3.3% | · | 9.5% | 7.6% | · | · | 37.0% | -11.5% | -12.5% | · | 19.0% | 8.5% | 8.5% | · | -6.4% | |
| ROIC | · | · | · | · | · | · | · | 14.6% | -1.7% | -1.6% | · | 6.0% | 3.5% | 3.2% | · | 2.5% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | 2.4 | · | 1.7 | 1.7 | · | · | 1.4 | 1.3 | 1.5 | · | 1.9 | 2.0 | 2.3 | · | 2.0 | |
| Quick Ratio | 2.6 | 2.1 | · | 1.5 | 1.5 | · | · | 1.4 | 1.2 | 1.3 | · | 1.7 | 1.8 | 2.1 | · | 1.8 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.4 | · | · | 1.1 | 1.8 | 2.0 | · | 2.6 | 3.3 | 3.8 | · | 4.4 | |
| LT Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.1 | · | · | 0.5 | 0.9 | 1.1 | · | 2.0 | 2.9 | 3.8 | · | 4.4 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -0.7 | · | 2.6 | 1.5 | 1.3 | · | 0.8 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.3 | · | · | 0.4 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Inventory Turnover | 1.1 | 1.2 | · | 2.0 | 1.4 | · | · | 7.0 | 1.3 | 2.0 | · | 2.4 | 1.7 | 2.4 | · | 2.0 | |
| Receivables Turnover | 1.9 | 1.7 | · | 1.2 | 1.9 | · | · | 1.9 | 1.6 | 1.6 | · | 2.0 | 1.7 | 1.8 | · | 2.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.71 | $2.52 | · | $2.29 | $2.10 | · | · | $1.45 | $1.00 | $1.06 | · | $0.81 | $0.65 | $0.55 | · | $0.49 | |
| Revenue / Share | $1.07 | $0.88 | · | $1.07 | $1.05 | · | · | $1.64 | $0.97 | $0.91 | · | $1.17 | $1.16 | $1.12 | · | $1.25 | |
| Cash Flow / Share | · | $0.30 | · | · | · | · | · | · | · | $0.23 | · | · | · | $0.06 | · | · | |
| Cash / Share | $0.71 | $0.71 | · | $1.06 | $1.10 | · | · | $1.37 | $1.39 | $1.59 | · | $1.72 | $1.28 | $1.32 | · | $1.71 | |
| EPS (TTM) | $0.52 | $0.48 | · | $0.75 | $0.99 | $0.28 | · | $0.47 | $0.18 | $0.32 | · | $0.08 | $-0.05 | $0.11 | · | $0.22 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $231M | $227M | · | $212M | $238M | $217M | · | $244M | $219M | $227M | · | $229M | $230M | $235M | · | $218M | |
| Net Income TTM | $27M | $24M | · | $37M | $48M | $14M | · | $23M | $9M | $15M | · | $4M | $-2M | $5M | · | $10M | |
| Market Cap | $414M | $325M | · | $268M | $171M | · | · | $125M | $158M | $256M | · | $125M | $166M | $144M | · | $108M | |
| Enterprise Value | $321M | $235M | · | $207M | $120M | · | · | $106M | $150M | $248M | · | $139M | $190M | $172M | · | $128M | |
| P/E | 15.6 | 13.3 | · | 7.1 | 3.5 | 10.6 | · | 5.4 | 18.1 | 16.6 | · | 32.9 | -70.6 | 28.1 | · | 10.8 | |
| P/S | 1.8 | 1.4 | · | 1.3 | 0.7 | · | · | 0.5 | 0.7 | 1.1 | · | 0.5 | 0.7 | 0.6 | · | 0.5 | |
| P/B | 3.0 | 2.5 | · | 2.3 | 1.6 | · | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Tangible Book | 3.0 | 2.5 | · | 2.3 | 1.6 | 1.5 | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Cash Flow | · | 21.1 | · | · | · | · | · | · | · | 22.7 | · | · | · | 54.6 | · | · | |
| EV / Revenue | 1.4 | 1.0 | · | 1.0 | 0.5 | · | · | 0.4 | 0.7 | 1.1 | · | 0.6 | 0.8 | 0.7 | · | 0.6 | |
| Earnings Yield | 6.4% | 7.5% | · | 14.1% | 28.9% | 9.5% | · | 18.4% | 5.5% | 6.0% | · | 3.0% | -1.4% | 3.6% | · | 9.3% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $228M | $230M | $236M | $228M | $253M |
| Faaliyet Kâr Marjı % | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% |
| Net Gelir | $31M | $30M | $22M | $2.0K | $-29M |
| Seyreltilmiş Hisse Başı Kâr | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 |
| Cari Oran | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 |
| Cari Oran | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $42M | $39M | $27M | $-16M | $21M |
Kurumsal Sahipler (13F) 172 dosya · $307.7M toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
172
Tutulan Değer
$307.7M
Yeni pozisyonlar
22
Çıkan pozisyonlar
15
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 22 (-8 önceki Ç'ye göre) | 15 (-1 önceki Ç'ye göre) | 60 (-1 önceki Ç'ye göre) | 53 (+16 önceki Ç'ye göre) | +896K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | $33.504.835 | 4.131.299 | 10,89% | Hisse senetleri |
| BlackRock, Inc. | $30.856.410 | 3.804.736 | 10,03% | Hisse senetleri |
| VANGUARD GROUP INC | $22.596.600 | 3.797.748 | 7,34% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $18.815.168 | 2.319.996 | 6,11% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $14.891.687 | 1.836.213 | 4,84% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.887.065 | 1.835.643 | 4,84% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $14.805.608 | 1.825.599 | 4,81% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $12.311.629 | 1.518.014 | 4,00% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $10.864.667 | 1.339.405 | 3,53% | Hisse senetleri |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $9.113.880 | 1.123.783 | 2,96% | Hisse senetleri |
| STATE STREET CORP | $7.722.058 | 952.165 | 2,51% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $7.082.082 | 873.253 | 2,30% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $6.420.006 | 791.616 | 2,09% | Hisse senetleri |
| RITHOLTZ WEALTH MANAGEMENT | $6.080.862 | 749.798 | 1,98% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $5.881.307 | 725.192 | 1,91% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $5.426.855 | 669.156 | 1,76% | Hisse senetleri |
| NORTHERN TRUST CORP | $5.290.851 | 652.386 | 1,72% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $5.214.292 | 642.946 | 1,69% | Hisse senetleri |
| UBS Group AG | $5.164.131 | 636.761 | 1,68% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $4.884.166 | 602.240 | 1,59% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4.318.170 | 532.450 | 1,40% | Hisse senetleri |
| SEI INVESTMENTS CO | $3.395.406 | 418.669 | 1,10% | Hisse senetleri |
| GLOBEFLEX CAPITAL L P | $3.104.565 | 382.807 | 1,01% | Hisse senetleri |
| Bank of New York Mellon Corp | $2.925.553 | 360.734 | 0,95% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $2.565.542 | 316.343 | 0,83% | Hisse senetleri |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2.506.850 | 309.106 | 0,81% | Hisse senetleri |
| Invesco Ltd. | $2.441.127 | 301.002 | 0,79% | Hisse senetleri |
| Russell Investments Group, Ltd. | $2.207.818 | 272.234 | 0,72% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $2.182.158 | 269.070 | 0,71% | Hisse senetleri |
| MORGAN STANLEY | $2.154.584 | 265.670 | 0,70% | Hisse senetleri |
| FEDERATED HERMES, INC. | $2.033.712 | 250.766 | 0,66% | Hisse senetleri |
| Empowered Funds, LLC | $1.786.763 | 220.316 | 0,58% | Hisse senetleri |
| PANAGORA ASSET MANAGEMENT INC | $1.764.290 | 217.545 | 0,57% | Hisse senetleri |
| PRUDENTIAL FINANCIAL INC | $1.732.288 | 213.599 | 0,56% | Hisse senetleri |
| JPMORGAN CHASE & CO | $1.730.866 | 211.339 | 0,56% | Hisse senetleri |
| FMR LLC | $1.714.811 | 211.444 | 0,56% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.526.562 | 188.232 | 0,50% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $1.395.001 | 172.010 | 0,45% | Hisse senetleri |
| Prospera Financial Services Inc | $1.287.530 | 158.762 | 0,42% | Hisse senetleri |
| Haven Private, LLC | $1.203.913 | 148.448 | 0,39% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $1.140.161 | 140.587 | 0,37% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $1.055.970 | 130.206 | 0,34% | Hisse senetleri |
| Round Rock Advisors LLC | $1.045.476 | 128.912 | 0,34% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.040.051 | 128.243 | 0,34% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $1.022.598 | 126.091 | 0,33% | Hisse senetleri |
| STRS OHIO | $686.106 | 84.600 | 0,22% | Hisse senetleri |
| Nuveen, LLC | $667.437 | 82.298 | 0,22% | Hisse senetleri |
| EVERGREEN CAPITAL MANAGEMENT LLC | $597.960 | 73.731 | 0,19% | Hisse senetleri |
| CANADA PENSION PLAN INVESTMENT BOARD | $596.085 | 73.500 | 0,19% | Hisse senetleri |
| Trexquant Investment LP | $585.729 | 72.223 | 0,19% | Hisse senetleri |
Aktivistler ve %5+ sahipler 7 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Alan H. Auerbach ×6 başvurular | 13 Aralık 2022 | · | İlk başvuru | Pasif yatırım | SEC |
| Kapil Munjal 2) | 04 Ekim 2011 | · | İlk başvuru | · | SEC |
| Faraaz Siddiqi 2) | 04 Ekim 2011 | · | İlk başvuru | · | SEC |
| Robert Johnson 2) | 04 Ekim 2011 | · | İlk başvuru | · | SEC |
| Robert Johnson | 21 Kasım 2007 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 19 Kasım 2007 | · | İlk başvuru | · | SEC |
| Faraaz Siddiqi | 19 Kasım 2007 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 24 içeriden öğrenenler · 10 yöneticiler · 12 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Alan H Auerbach | President and CEO | 06 Temmuz 2026 S | 7.261.671 | 0 | 3 | $-568.748 |
| Maximo F Nougues | Chief Financial Officer | 06 Temmuz 2026 S | 230.637 | 0 | 3 | $-141.703 |
| Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | 06 Temmuz 2026 S | 196.841 | 0 | 3 | $-122.564 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | 07 Şubat 2025 A | 156.792 | 0 | 0 | $0 |
| Alvin F Wong | Chief Scientific Officer | 12 Şubat 2024 A | 141.241 | 0 | 0 | $0 |
| Richard Paul Bryce | Title of Reporting Person: Chief Medical and Scientific Officer | 05 Nisan 2021 S | 121.662 | 0 | 0 | $0 |
| Steven Lo | Chief Commercial Officer | 22 Temmuz 2019 S | 19.557 | 0 | 0 | $0 |
| Charles R Eyler | Title of Reporting Person: Senior Vice President, Finance and Administration and Treasurer | 04 Şubat 2019 S | 31.957 | 0 | 0 | $0 |
| Robert Charnas | The Reporting Person is the Senior Vice President of Regulatory Affairs and Project Management of the Issuer. | 16 Şubat 2017 A | 26.453 | 0 | 0 | $0 |
| Richard Benton Phillips | The Reporting Person is the Interim Head of Regulatory Affairs, Quality Assurance and Pharmacovigilance of the Issuer. | 15 Nisan 2016 A | · | 0 | 0 | $0 |
| Alessandra Cesano | Yönetim kurulu üyesi | 14 Eylül 2026 M | 56.700 | 0 | 1 | $-566.808 |
| Troy Edward Wilson | Yönetim kurulu üyesi | 14 Eylül 2026 S | 54.750 | 0 | 2 | $-123.260 |
| Brian M Stuglik | Yönetim kurulu üyesi | 12 Haziran 2026 S | 113.858 | 0 | 1 | $-58.320 |
| Allison Dorval | Yönetim kurulu üyesi | 12 Haziran 2026 S | 90.780 | 0 | 1 | $-83.592 |
| Adrian Senderowicz | Yönetim kurulu üyesi | 12 Haziran 2026 S | 27.000 | 0 | 1 | $-194.400 |
| Jay M Moyes | Yönetim kurulu üyesi | 12 Haziran 2026 S | 58.322 | 0 | 1 | $-158.840 |
| MILLER MICHAEL PATRICK | Yönetim kurulu üyesi | 11 Haziran 2026 A | 81.000 | 0 | 1 | $-97.200 |
| Ann Calby Miller | Yönetim kurulu üyesi | 15 Haziran 2021 A | 40.732 | 0 | 0 | $0 |
| Hugh O'Dowd | Yönetim kurulu üyesi | 09 Haziran 2020 A | 25.748 | 0 | 0 | $0 |
| Frank Zavrl | Yönetim kurulu üyesi | 09 Haziran 2020 A | 50.993 | 0 | 0 | $0 |
| Thomas Malley | Yönetim kurulu üyesi | 15 Aralık 2014 A | 156.551 | 0 | 0 | $0 |
| Faraaz Siddiqi | · | 04 Ekim 2011 D | 0 | 0 | 0 | $0 |
| Kapil Munjal | · | 04 Ekim 2011 D | 0 | 0 | 0 | $0 |
| Robert Andrew Johnson | · | 04 Ekim 2011 D | 0 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 25 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| ROSC · Lattice Strategies Trust | 0,71% | 55.155 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,56% | 231.071 SH | 01 Ekim 2026 | Günlük |
| IWC · iShares Trust | 0,10% | 149.805 SH | 11 Eylül 2026 | Günlük |
| VFQY · VANGUARD WELLINGTON FUND | 0,06% | 34.260 SH | 19 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 3.640 SH | 01 Ekim 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 55.175 SH | 01 Ekim 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 32.358 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,01% | 1.181.450 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 21.135 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,01% | 16.014 SH | 19 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 254.380 SH | 19 Ağustos 2026 | Günlük |
| DFAT · Dimensional ETF Trust | 0,01% | 172.951 NS | 31 Temmuz 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 170.404 NS | 31 Temmuz 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,01% | 81.441 NS | 31 Temmuz 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 3.611 NS | 31 Temmuz 2026 | N-PORT |
| IWO · iShares Trust | 0,00% | 67.004 SH | 11 Eylül 2026 | Günlük |
| DCOR · Dimensional ETF Trust | 0,00% | 6.348 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 12.537 NS | 31 Temmuz 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 15.090 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 12.376 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 446.899 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.343.121 SH | 19 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.680 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.979 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 357.993 SH | 11 Eylül 2026 | Günlük |
PBYI Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 6 analist
SAT
Medyan hedef
$6.00
-36,9%
0 0,0%
Güçlü Al
0 0,0%
Al
3 50,0%
Tut
1 16,7%
Sat
2 33,3%
Güçlü Sat
12 Aylık Fiyat Hedefi
1 analist · 2026-08-18Ortalama hedef $6.00 -36,9%
Düşük$6.00
Ortalama$6.00
Yüksek$6.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| MNPR | · | · | · | · | · | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | · |
| TECX | $391M | -5.2 | · | · | -27.7% | · |
| DMAC | $428M | · | · | · | -78.7% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 6, 2026